Reprogramming CAR with cytokine signaling increases the efficacy of CAR-T cell therapy in solid tumour treatment and confers sustained immune memory [Tumor infiltrated CAR-T cells]
RNA-seq (gene expression) · human · 10 samples
- What it is
- RNA-seq (gene expression)Gene activity measured by sequencing. The summary does not mention single-cell work, so this is most likely bulk: one average per sample, the usual starting point for comparing groups.
- Organism
- Homo sapiens (human)
- Samples
- 10 samples: 5 × Tumor infiltrated 28Z CAR-T cells, 15 days, vs 5 × Tumor infiltrated S71 CAR-T cells, 15 days,Groups are read from the sample names, not from the paper. Check the list below.
- Data you can get
- A processed table (series matrix) and supplementary files from NCBI; the raw sequencing reads from ENA. Which of these hold counts depends on the study, so check the file list.
Read the full summary ↓
Direct links to NCBI and ENA, no account and no request form. Pick by what you want to do: take the small processed table to look, the supplementary files to re-analyse, or the original raw data to start over.
Processed table
The series matrix: one table of values per sample as the submitters processed it. The smallest download, and it opens in Excel or R. Start here to see what the data look like.
Supplementary files
The count tables and other files the authors uploaded. Take only the samples you need, or the whole study as GSE328225_RAW.tar (it can run to tens of gigabytes).
Raw sequencing reads
The original FASTQ files, straight from the sequencer, held at ENA. Large, and you align them yourself, so only choose this if you need to re-process the study from scratch.
What the files usually look like: For RNA-seq the counts are usually a table among the supplementary files (look for 'counts', 'expression', 'FPKM' or 'TPM' in the file name). The series matrix of a sequencing study is sometimes nearly empty.
Also filed as BioProject PRJNA1454390 and SRA study SRP692395. Searching any of these in the dataset finder brings you back here.
Supports a between-group comparison across 10 samples.
How we read this: 2 replicated groups read from 10 sample titles; they account for 10 of them. These groups are guessed from the sample names, not taken from the paper, so check them against the sample list below before relying on them.
- GSM9675255 Tumor infiltrated 28Z CAR-T cells, 15 days, rep1 Tumor infiltrated 28Z C…
- GSM9675256 Tumor infiltrated 28Z CAR-T cells, 15 days, rep2 Tumor infiltrated 28Z C…
- GSM9675257 Tumor infiltrated 28Z CAR-T cells, 15 days, rep3 Tumor infiltrated 28Z C…
- GSM9675258 Tumor infiltrated 28Z CAR-T cells, 15 days, rep4 Tumor infiltrated 28Z C…
- GSM9675259 Tumor infiltrated 28Z CAR-T cells, 15 days, rep5 Tumor infiltrated 28Z C…
- GSM9675260 Tumor infiltrated S71 CAR-T cells, 15 days, rep1 Tumor infiltrated S71 C…
- GSM9675261 Tumor infiltrated S71 CAR-T cells, 15 days, rep2 Tumor infiltrated S71 C…
- GSM9675262 Tumor infiltrated S71 CAR-T cells, 15 days, rep3 Tumor infiltrated S71 C…
- GSM9675263 Tumor infiltrated S71 CAR-T cells, 15 days, rep4 Tumor infiltrated S71 C…
- GSM9675264 Tumor infiltrated S71 CAR-T cells, 15 days, rep5 Tumor infiltrated S71 C…
- GSE322796 Persistence of mucosal CAR-T cells and inflammatory remodeling in enterocolitis associated with BCMA CAR-T cell therapy 23 samples shares car-t, car
- GSE323364 Coordinating catalytic and non-canonical functions of EZH2 sensitizes tumors to CAR-T cell therapy 42 samples shares car-t, car
- GSE246342 CD4+ CAR-T cell exhaustion associated with early relapse of multiple myeloma after BCMA CAR-T cell therapy I 18 samples shares car-t, car
- GSE326661 Reprogramming engineered autologous T cells to overcome resistance in Merkel cell carcinoma [scRNA-seq] 22 samples shares car, reprogramming
- GSE316195 A Phase 1 clinical trial and single-cell correlates of motixafortide, cemiplimab, gemcitabine and nab-paclitaxel for metastatic treatment-naïve metastatic pancreatic ductal adenocarcinoma. 22 samples shares car, treatment
- GSE290925 Single-Cell Transcriptomic Profiling of the Tumor Microenvironment in Treatment-Naive Hepatocellular Carcinoma Patients 12 samples shares car, treatment
- GSE109211 Molecular predictors of prevention of recurrence in hepatocellular carcinoma with sorafenib as adjuvant treatment in the phase 3 STORM trial 140 samples shares car, treatment
- GSE262166 Treatment of cholangiocarcinoma using humanized monoclonal antibodies targeting Claudin-1 77 samples shares car, treatment
Metadata from NCBI GEO, cached and refreshed periodically — the NCBI page above is authoritative. Downloads link straight to NCBI/ENA; nothing is proxied through BioTransfer.